

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**May 20, 2011**

---

**AMGEN INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-12477**  
(Commission  
File Number)

**95-3540776**  
(IRS Employer  
Identification No.)

**One Amgen Center Drive  
Thousand Oaks, California**  
(Address of principal executive offices)

**91320-1799**  
(Zip Code)

**805-447-1000**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

The Company held its Annual Meeting of Stockholders on May 20, 2011. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows:

**Item 1 - Election of Directors**

Each of the following 12 nominees for director were elected to serve a one-year term expiring at the Company's 2012 Annual Meeting of Stockholders.

<b>Name</b>	<b>Votes For</b>	<b>Votes Against</b>	<b>Abstain</b>	<b>Broker Non-Votes</b>
Dr. David Baltimore	582,828,712	121,546,553	3,963,576	97,107,133
Mr. Frank J. Biondi, Jr.	616,742,168	86,752,259	4,844,414	97,107,133
Mr. François de Carbonnel	581,543,546	121,832,088	4,963,207	97,107,133
Dr. Vance D. Coffman	582,141,277	121,267,372	4,930,192	97,107,133
Dr. Rebecca M. Henderson	582,216,541	121,241,068	4,881,232	97,107,133
Mr. Frank C. Herringer	566,697,965	136,724,853	4,916,023	97,107,133
Dr. Gilbert S. Omenn	675,969,133	28,390,527	3,979,181	97,107,133
Ms. Judith C. Pelham	675,256,425	28,343,007	4,739,409	97,107,133
Admiral J. Paul Reason, USN (Retired)	656,275,294	47,900,173	4,163,374	97,107,133
Mr. Leonard D. Schaeffer	657,737,153	46,437,617	4,164,071	97,107,133
Mr. Kevin W. Sharer	657,823,118	46,878,730	3,636,993	97,107,133
Dr. Ronald D. Sugar	622,544,828	81,549,176	4,244,837	97,107,133

**Item 2 - Ratification of Selection of Independent Registered Public Accountants**

Ernst & Young LLP was ratified as the Company's independent registered public accountants for the fiscal year ending December 31, 2011. No Broker Non-Votes resulted from the vote on this proposal.

For:	793,657,902
Against:	8,368,199
Abstain:	3,419,873

**Item 3 - Advisory Vote on Executive Compensation**

The advisory vote on executive compensation was approved.

For:	393,700,304
Against:	309,162,287
Abstain:	5,476,250
Broker Non-Votes:	97,107,133

**Item 4 - Advisory Vote on Frequency of Future Stockholder Advisory Votes on Executive Compensation**

One year was selected for the advisory vote on the frequency of future stockholder advisory votes on executive compensation.

One year:	629,413,248
Two years:	3,456,971
Three years:	71,428,963
Abstain:	4,039,660
Broker Non-Votes:	97,107,133

**Item 5 - Stockholder Proposal**

**Stockholder Proposal #1**

The stockholder proposal relating to shareholder action by written consent was approved.

For:	355,515,202
Against:	345,480,290
Abstain:	7,343,349
Broker Non-Votes:	97,107,133

The above voting results represent 50.19% approval under the required voting standard (based on votes present or represented by proxy and entitled to vote) or 50.19% approval of the votes cast and 38.10% approval of the outstanding shares.

No other matters were submitted for stockholder action.

A copy of the press release announcing the vote results is furnished as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release, dated May 20, 2011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMGEN INC.

Date: May 20, 2011

By: /s/ David J. Scott

Name: David J. Scott

Title: Senior Vice President, General Counsel and Secretary

**EXHIBIT INDEX**

**Exhibit  
No.**

**Document Description**

99.1 Press Release, dated May 20, 2011



One Amgen Center Drive  
Thousand Oaks, CA 91320-1799  
Telephone (805) 447-1000  
Fax (805) 499-3507  
www.Amgen.com

*News Release*

---

### **AMGEN ANNOUNCES VOTING RESULTS OF ANNUAL MEETING OF STOCKHOLDERS**

SEATTLE (May 20, 2011) - Amgen (NASDAQ: AMGN), today announced results of voting at the Company's Annual Meeting of Stockholders, held at The Fairmont Olympic Hotel in Seattle, Wash. Approximately 86.32 percent of outstanding shares were represented at the meeting.

The director nominees David Baltimore, Frank J. Biondi, Jr., François de Carbonnel, Vance D. Coffman, Rebecca M. Henderson, Frank C. Herrerger, Gilbert S. Omenn, Judith C. Pelham, J. Paul Reason, USN (Retired), Leonard D. Schaeffer, Kevin W. Sharer and Ronald D. Sugar were each reelected to Amgen's Board of Directors, each receiving a majority of 'For' votes of the votes cast. With the reelection of these directors, Amgen currently has 12 directors.

With approximately 98.54 percent of 'For' votes of the votes cast, stockholders ratified Ernst & Young as Amgen's independent registered public accountants for the year ending Dec. 31, 2011.

Stockholders approved an advisory vote, commonly known as "Say-on-Pay." The non-binding proposal gives shareholders the opportunity to endorse or not endorse executive pay programs and policies. Say-on-Pay received approximately 55.58 percent of the votes cast 'For' the proposal. In connection with this advisory vote, stockholders voted that executive compensation should be voted on annually at 89.37 percent of the votes cast.

Stockholders approved a nonbinding resolution recommending that the Company take steps to permit shareholders to act by the written consent of the majority of shares outstanding. The proposal received approximately 50.19 percent of votes cast 'For' the proposal and approximately 38.10 percent of the votes outstanding 'For' the proposal.

#### **About Amgen**

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit [www.amgen.com](http://www.amgen.com).

### Forward Looking Statements

This release contains forward-looking statements that are based on management's current expectations and beliefs. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements regarding: Amgen's intention to initiate a quarterly common stock dividend; the planned repurchase of our common stock; the planned return of capital to stockholders; expected payout ratios; the anticipated revenues of our products, including Prolia and XGEVA; our business strategy and future capital position; estimates of dividend distributions, stock repurchases, revenues, operating margins, capital expenditures, cash or other financial metrics in any current or future period; expected legal, arbitration, political, regulatory or clinical results or practices; customer and prescriber patterns or practices; reimbursement activities and outcomes; and other such estimates and results. Forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those described, including those risks discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and subsequent reports on Form 10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this information as of May 20, 2011 and expressly disclaims any duty to update information contained in this presentation.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market products worldwide, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and worldwide trends toward managed care and healthcare cost containment as well as legislation affecting pharmaceutical pricing and reimbursement. Our research, development, testing, pricing, marketing and other operations are subject to extensive regulation by government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Our business performance could affect or limit our ability to repurchase our common stock or the ability of the Amgen Inc. Board of Directors to declare a dividend.

Contact: Amgen, Thousand Oaks  
Christine Regan: 805-447-5476 (media)  
Arvind Sood: 805-447-1060 (investors)